Psoriatic Arthritis

More severe psoriasis associated with clinically significant cardiovascular risk.

This activity is supported by educational grants from AbbVie Inc and LEO Pharma Inc.

Secukinumab improved peripheral joint disease, prevented joint damage, and produced clear or almost clear skin in a pair of pivotal Phase 3 trials.

Assessing a patient's sense of balance and hearing ability may be an aid in diagnosing psoriatic arthritis.

Early diagnosis is the key to successful management of psoriatic arthritis, and treatment of this inflammatory disease is largely dependent on which symptoms are predominant.

Grocery store chain joins growing list of major companies offering enhanced specialty pharmacy.

Patients who responded to brodalumab showed improvement in skin condition and joint swelling.

Recommendations for co-morbidities identified as an important step for the optimal care of patients.

Methotrexate, a traditional disease-modifying antirheumatic drug, may enhance the likelihood of therapeutic persistence with novel biologic agents.

Questionnaires given to patients with psoriasis predicted probable psoriatic arthritis in a significant number of patients.

Biologic agent golimumab effective over 5-year span in treating disease symptoms and improving quality of life.

Cardiovascular risk related to severity of inflammation, but not associated with disease duration.

Patients with psoriasis, psoriatic arthritis, or both conditions felt that their quality of life decreased if they experienced condition symptoms in more parts of their body.

A study suggests that patients with ankylosing spondylitis and psoriatic arthritis have more cardiac risk factors than age- and gender-matched controls.

The reason for discontinuing tumor necrosis factor (TNF)–alpha inhibitor therapy in severe psoriasis or psoriatic arthritis patients may correlate to how well they respond to treatment with a different TNF-alpha inhibitor.

Celgene's apremilast (Otezla) was found to alleviate joint pain and inflammation during clinical trials.

Apremilast (Otezla) is the first oral therapy FDA approved to improve signs and symptoms, including physical functioning for patients with this condition.

A recent study compared the annual cost per treated patient for a health plan for patients taking etanercept, adalimumab, or infliximab.

Humira, Abbott's biggest seller, was recently approved by the FDA to treat ulcerative colitis.

A new study finds that patients with autoimmune diseases being treated with immunosuppressive drugs are not at an increased risk of developing shingles.